A draft of the MDMA/PTSD protocol that MAPS has been working for 2 years to develop, with Dr. Michael Mithoefer and Mark Wagner, Ph.D., at the Medical University of South Carolina, has now been posted to the web. The protocol will submitted to FDA shortly after NIDA’s scientific meeting on MDMA, held at the National Institutes of Health campus in Bethesda, MD, on July 19-20. If and when it becomes approved in some form, this protocol will be the first FDA-approved study of the therapeutic use of MDMA since MDMA was placed in Schedule 1 in 1985.